175 related articles for article (PubMed ID: 18293383)
1. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.
Maris JM; Courtright J; Houghton PJ; Morton CL; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2008 Jul; 51(1):42-8. PubMed ID: 18293383
[TBL] [Abstract][Full Text] [Related]
2. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
Maris JM; Courtright J; Houghton PJ; Morton CL; Gorlick R; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2008 Mar; 50(3):581-7. PubMed ID: 17457854
[TBL] [Abstract][Full Text] [Related]
3. Initial testing of dasatinib by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Houghton PJ; Morton CL; Lock RB; Tajbakhsh M; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
Pediatr Blood Cancer; 2008 Jun; 50(6):1198-206. PubMed ID: 17914733
[TBL] [Abstract][Full Text] [Related]
4. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.
Houghton PJ; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Wu J; Smith MA
Pediatr Blood Cancer; 2010 Jul; 54(7):921-6. PubMed ID: 20166202
[TBL] [Abstract][Full Text] [Related]
5. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
Smith MA; Morton CL; Phelps DA; Kolb EA; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Wu J; Houghton PJ
Pediatr Blood Cancer; 2008 Jul; 51(1):34-41. PubMed ID: 18260120
[TBL] [Abstract][Full Text] [Related]
6. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
[TBL] [Abstract][Full Text] [Related]
7. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.
Keir ST; Maris JM; Lock R; Kolb EA; Gorlick R; Carol H; Morton CL; Reynolds CP; Kang MH; Watkins A; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2010 Dec; 55(6):1126-33. PubMed ID: 20672370
[TBL] [Abstract][Full Text] [Related]
8. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
Carol H; Lock R; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
Pediatr Blood Cancer; 2009 Dec; 53(7):1255-63. PubMed ID: 19554570
[TBL] [Abstract][Full Text] [Related]
9. Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.
Lock RB; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak AW; Gorlick R; Kolb EA; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2012 Jun; 58(6):916-23. PubMed ID: 21584937
[TBL] [Abstract][Full Text] [Related]
10. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Houghton PJ; Morton CL; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
Pediatr Blood Cancer; 2008 Jun; 50(6):1190-7. PubMed ID: 18260118
[TBL] [Abstract][Full Text] [Related]
11. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.
Houghton PJ; Morton CL; Kolb EA; Gorlick R; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
Pediatr Blood Cancer; 2008 Apr; 50(4):799-805. PubMed ID: 17635004
[TBL] [Abstract][Full Text] [Related]
12. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
Gorlick R; Kolb EA; Keir ST; Maris JM; Reynolds CP; Kang MH; Carol H; Lock R; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2014 Jan; 61(1):158-64. PubMed ID: 23956067
[TBL] [Abstract][Full Text] [Related]
13. Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.
Gorlick R; Kolb EA; Houghton PJ; Morton CL; Neale G; Keir ST; Carol H; Lock R; Phelps D; Kang MH; Reynolds CP; Maris JM; Billups C; Smith MA
Pediatr Blood Cancer; 2012 Dec; 59(7):1266-74. PubMed ID: 22315240
[TBL] [Abstract][Full Text] [Related]
14. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.
Lock R; Carol H; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Wu J; Smith MA
Pediatr Blood Cancer; 2008 Jun; 50(6):1181-9. PubMed ID: 18085673
[TBL] [Abstract][Full Text] [Related]
15. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Lock R; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2011 Apr; 56(4):595-603. PubMed ID: 21298745
[TBL] [Abstract][Full Text] [Related]
16. Initial testing of cisplatin by the pediatric preclinical testing program.
Tajbakhsh M; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Maris JM; Keir ST; Wu J; Reynolds CP; Smith MA; Lock RB
Pediatr Blood Cancer; 2008 May; 50(5):992-1000. PubMed ID: 17554786
[TBL] [Abstract][Full Text] [Related]
17. Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.
Lock R; Carol H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Purmal A; Gudkov A; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27650817
[TBL] [Abstract][Full Text] [Related]
18. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
Smith MA; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ
Pediatr Blood Cancer; 2012 Aug; 59(2):246-53. PubMed ID: 22012946
[TBL] [Abstract][Full Text] [Related]
19. Initial testing of topotecan by the pediatric preclinical testing program.
Carol H; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Maris JM; Keir ST; Watkins A; Smith MA; Lock RB
Pediatr Blood Cancer; 2010 May; 54(5):707-15. PubMed ID: 20017204
[TBL] [Abstract][Full Text] [Related]
20. Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.
Kurmasheva RT; Sammons M; Favours E; Wu J; Kurmashev D; Cosmopoulos K; Keilhack H; Klaus CR; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27555605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]